Our prior work indicated that, even without estrogen present, some ER-positive tumors continued to grow in the obese environment [9], and breast cancer endocrine therapy resistance is more frequent in patients with obesity [50, 51]. This evidence concerns the gene ESR1 and obesity due to melanocortin 4 receptor deficiency.